Physician profile
Jeff A Benjamin
NPI 1821057779
$11,315.32
in general payments reported to CMS, 2019-2025
62 companies · $47.37 in 2025
The $47.37 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,690 · 2020: $789 · 2021: $1,676 · 2022: $2,804 · 2023: $3,183 · 2024: $125 · 2025: $47.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322 · Education: $33.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.58 |
| Education | $33.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,623.83 | 2019-2023 | Austedo Xr, Austedo |
| Abbvie INC. | $1,124.51 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Acadia Pharmaceuticals INC | $1,088.24 | 2019-2023 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $847.31 | 2021 | |
| Neurocrine Biosciences, INC. | $782.03 | 2019-2023 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $666.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $562.30 | 2019-2022 | |
| Emd Serono, INC. | $304.68 | 2019-2023 | Mavenclad |
| Ucb, INC. | $271.91 | 2019-2023 | Briviact |
| Amgen INC. | $261.51 | 2019-2023 | Aimovig |
| Genzyme Corporation | $232.09 | 2019-2020 | |
| Eisai INC. | $227.49 | 2019-2023 | |
| Lundbeck LLC | $212.14 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $173.71 | 2019-2023 | Ultomiris |
| Genentech USA, INC. | $167.11 | 2019-2023 | Ocrevus, Enspryng |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.